Case-Based Peer Perspectives: A 72-Year-Old Man With Relapsed/Refractory Multiple Myeloma (RRMM) : Episode 5
Additional Toxicities in GPRC5D-Directed Bispecifics for RRMM
Panelist discusses how, based on the patient achieving sCR with emerging oral, skin, and nail toxicities, panelist would recommend initiating supportive care, including oral hygiene protocols, topical treatments, and prophylactic nail care. These toxicities are generally less severe than those of BCMA-targeted bispecifics, which often present with more systemic CRS and neurotoxicity.
Video content above is prompted by the following:
- After the first month of treatment, the patient achieved stringent complete response (sCR) but is experiencing the following symptoms: oral, skin, and nail toxicities.
- What mitigation strategies would you initiate for this patient?
- How do those toxicities compare with those of other bispecifics (ie, BCMA-directed) in this space?
Recent Videos
Related Content
Supportive Care Helps Manage AEs With Teclistamab in R/R Multiple Myeloma
December 13th 2024Article
During a Case-Based Roundtable® event, Hana Safah, MD, discussed updated data and adverse event management related to teclistamab in patients with multiple myeloma in the second article of a 2-part series.
Read More
